In $4.1B deal, Thermo Fisher buys 3M spinoff's filtration unit to beef up bioproduction

On the heels of a move to reduce its viral vector manufacturing workforce, Thermo Fisher is beefing up its biologics production business through a $4.1 billion acquisition.

The buyout target is Solventum’s purification and filtration business, which generated about $1 billion in revenue last year and is expected to grow sales at mid- to high-single-digit percentages in the future, according to Thermo Fisher.